Sustained Release of Prindopril Erbumine from Its Chitosan-coated Magnetic Nanoparticles for Biomedical Applications

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2013 Dec 5

PMID 24300098

Citations 10

Authors

Dena Dorniani

Mohd Zobir Bin Hussein

Aminu Umar Kura

Sharida Fakurazi

Abdul Halim Shaari

Zalinah Ahmad

Affiliations

Soon will be listed here.

Abstract

The preparation of magnetic nanoparticles coated with chitosan-prindopril erbumine was accomplished and confirmed by X-ray diffraction, TEM, magnetic measurements, thermal analysis and infrared spectroscopic studies. X-ray diffraction and TEM results demonstrated that the magnetic nanoparticles were pure iron oxide phase, having a spherical shape with a mean diameter of 6 nm, compared to 15 nm after coating with chitosan-prindopril erbumine (FCPE). Fourier transform infrared spectroscopy study shows that the coating of iron oxide nanoparticles takes place due to the presence of some bands that were emerging after the coating process, which belong to the prindopril erbumine (PE). The thermal stability of the PE in an FCPE nanocomposite was remarkably enhanced. The release study showed that around 89% of PE could be released within about 93 hours by a phosphate buffer solution at pH 7.4, which was found to be of sustained manner governed by first order kinetic. Compared to the control (untreated), cell viability study in 3T3 cells at 72 h post exposure to both the nanoparticles and the pure drug was found to be sustained above 80% using different doses.

Citing Articles

Role of Organic and Inorganic Nanoparticles in the Drug Delivery System for Hypertension Treatment: A Systematic Review.

Moradifar N, Kiani A, Veiskaramian A, Karami K Curr Cardiol Rev. 2022; 18(1):e110621194025.

PMID: 35297343 PMC: 9241118. DOI: 10.2174/1573403X17666210611115823.

Hepatotoxic and Neurotoxic Potential of Iron Oxide Nanoparticles in Wistar Rats: a Biochemical and Ultrastructural Study.

Mabrouk M, Fouad G, El-Sayed S, Rizk M, Beherei H Biol Trace Elem Res. 2021; 200(8):3638-3665.

PMID: 34704196 DOI: 10.1007/s12011-021-02943-4.

Recent development for biomedical applications of magnetic nanoparticles.

Khan A, Chen L, Ge G Inorg Chem Commun. 2021; 134:108995.

PMID: 34658663 PMC: 8500685. DOI: 10.1016/j.inoche.2021.108995.

Synergistic Theranostics of Magnetic Resonance Imaging and Photothermal Therapy of Breast Cancer Based on the Janus Nanostructures FeO-Au-PEG.

Kang X, Sun T, Zhang L, Zhou C, Xu Z, Du M Int J Nanomedicine. 2021; 16:6383-6394.

PMID: 34556986 PMC: 8455180. DOI: 10.2147/IJN.S322894.

Synthesis and properties of magnetic nanotheranostics coated with polyethylene glycol/5-fluorouracil/layered double hydroxide.

Ebadi M, Saifullah B, Buskaran K, Hussein M, Fakurazi S Int J Nanomedicine. 2019; 14:6661-6678.

PMID: 31695362 PMC: 6707435. DOI: 10.2147/IJN.S214923.

References

Hussein Al Ali S, Al-Qubaisi M, Hussein M, Ismail M, Zainal Z, Hakim M . Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite. Int J Nanomedicine. 2012; 7:2129-41. PMC: 3356206. DOI: 10.2147/IJN.S30461. View

Dorniani D, Hussein M, Kura A, Fakurazi S, Shaari A, Ahmad Z . Preparation of Fe₃O₄ magnetic nanoparticles coated with gallic acid for drug delivery. Int J Nanomedicine. 2012; 7:5745-56. PMC: 3500033. DOI: 10.2147/IJN.S35746. View

Schweiger C, Pietzonka C, Heverhagen J, Kissel T . Novel magnetic iron oxide nanoparticles coated with poly(ethylene imine)-g-poly(ethylene glycol) for potential biomedical application: synthesis, stability, cytotoxicity and MR imaging. Int J Pharm. 2011; 408(1-2):130-7. DOI: 10.1016/j.ijpharm.2010.12.046. View

Neu M, Fischer D, Kissel T . Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J Gene Med. 2005; 7(8):992-1009. DOI: 10.1002/jgm.773. View

Bertrand M . Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin. 2004; 20(10):1559-69. DOI: 10.1185/030079904X4185. View

Ge Y, Zhang Y, Xia J, Ma M, He S, Nie F . Effect of surface charge and agglomerate degree of magnetic iron oxide nanoparticles on KB cellular uptake in vitro. Colloids Surf B Biointerfaces. 2009; 73(2):294-301. DOI: 10.1016/j.colsurfb.2009.05.031. View

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-52. DOI: 10.1161/01.HYP.0000107251.49515.c2. View

Jain T, Morales M, Sahoo S, Leslie-Pelecky D, Labhasetwar V . Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm. 2005; 2(3):194-205. DOI: 10.1021/mp0500014. View

Clark L . Safety profile of perindopril. Am J Cardiol. 2001; 88(7A):36i-40i. DOI: 10.1016/s0002-9149(01)01920-8. View

10.

Pascard C, GUILHEM J, Vincent M, Remond G, Portevin B, LAUBIE M . Configuration and preferential solid-state conformations of perindoprilat (S-9780). Comparison with the crystal structures of other ACE inhibitors and conclusions related to structure-activity relationships. J Med Chem. 1991; 34(2):663-9. DOI: 10.1021/jm00106a030. View

11.

Burt V, Cutler J, Higgins M, Horan M, Labarthe D, Whelton P . Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension. 1995; 26(1):60-9. DOI: 10.1161/01.hyp.26.1.60. View

12.

Yasin Y, Ismail N, Hussein M, Aminudin N . Synthesis and characterization of lawsone-lntercalated Zn-Al-layered double hydroxides. J Biomed Nanotechnol. 2011; 7(3):486-8. DOI: 10.1166/jbn.2011.1307. View

13.

Qu J, Shao H, Jing G, Huang F . PEG-chitosan-coated iron oxide nanoparticles with high saturated magnetization as carriers of 10-hydroxycamptothecin: preparation, characterization and cytotoxicity studies. Colloids Surf B Biointerfaces. 2012; 102:37-44. DOI: 10.1016/j.colsurfb.2012.08.004. View

14.

Remkova A, Kratochvilova H, Durina J . Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. J Hum Hypertens. 2008; 22(5):338-45. DOI: 10.1038/sj.jhh.1002328. View

15.

Lind K, Kresse M, Debus N, Muller R . A novel formulation for superparamagnetic iron oxide (SPIO) particles enhancing MR lymphography: comparison of physicochemical properties and the in vivo behaviour. J Drug Target. 2002; 10(3):221-30. DOI: 10.1080/10611860290022651. View

16.

Saifullah B, Hussein M, Hussein-Al-Ali S, Arulselvan P, Fakurazi S . Sustained release formulation of an anti-tuberculosis drug based on para-amino salicylic acid-zinc layered hydroxide nanocomposite. Chem Cent J. 2013; 7(1):72. PMC: 3651359. DOI: 10.1186/1752-153X-7-72. View

17.

Kura A, Hussein Al Ali S, Hussein M, Fakurazi S, Arulselvan P . Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. Int J Nanomedicine. 2013; 8:1103-10. PMC: 3604971. DOI: 10.2147/IJN.S39740. View

18.

Ankamwar B, Lai T, Huang J, Liu R, Hsiao M, Chen C . Biocompatibility of Fe(3)O(4) nanoparticles evaluated by in vitro cytotoxicity assays using normal, glia and breast cancer cells. Nanotechnology. 2010; 21(7):75102. DOI: 10.1088/0957-4484/21/7/075102. View

19.

Wong J, Patel R, Kowey P . The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis. 2004; 47(2):116-30. DOI: 10.1016/j.pcad.2004.04.003. View

20.

Agnihotri S, Mallikarjuna N, Aminabhavi T . Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004; 100(1):5-28. DOI: 10.1016/j.jconrel.2004.08.010. View